<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" VersionID="2" Owner="NLM" IndexingMethod="Automated"><PMID Version="2">35688956</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>10</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Use and subjective experience of the impact of motor-assisted movement exercisers in people with amyotrophic lateral sclerosis: a multicenter observational study.</ArticleTitle><Pagination><StartPage>9657</StartPage><MedlinePgn>9657</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">9657</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-022-13761-6</ELocationID><Abstract><AbstractText>Motor-assisted movement exercisers (MME) are devices that assist with physical therapy in domestic settings for people living with ALS. This observational&#xa0;cross-sectional study assesses the subjective experience of the therapy and&#xa0;analyzes users' likelihood of recommending treatment with MME. The&#xa0;study was implemented in ten ALS centers between February 2019 and October 2020, and was coordinated by the research platform Ambulanzpartner. Participants assessed symptom severity, documented frequency of MME use and rated the subjective benefits of therapy on a numerical scale (NRS, 0 to 10 points, with 10 being the highest). The Net Promotor Score (NPS) determined the likelihood of a participant recommending MME. Data for 144 participants were analyzed. Weekly MME use ranged from 1 to 4 times for 41% of participants, 5 to 7 times for 42%, and over 7 times for 17%. Particularly positive results were recorded in the following domains: amplification of a sense of achievement (67%), diminution of the feeling of having rigid limbs (63%), diminution of the feeling of being immobile (61%), improvement of general wellbeing (55%) and reduction of muscle stiffness (52%). Participants with more pronounced self-reported muscle weakness were more likely to note a beneficial effect on the preservation and improvement of muscle strength during MME treatment (p&#x2009;&lt;&#x2009;0.05). Overall, the NPS for MME was high (+&#x2009;61). High-frequency MME-assisted treatment (defined as a minimum of five sessions a week) was administered in the majority of participants (59%) in addition to physical therapy. Most patients reported having achieved their individual therapeutic objectives, as evidenced by a high level of satisfaction with MME therapy. The results bolster the justification for extended MME treatment as part of a holistic approach to ALS care.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Maier</LastName><ForeName>Andr&#xe9;</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Outpatient Center for ALS and Other Motor Neuron Diseases, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t Zu Berlin and Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany. andre.maier@charite.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaudlitz</LastName><ForeName>Marcel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Ambulanzpartner Soziotechnologie APST GmbH, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grehl</LastName><ForeName>Torsten</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Alfried Krupp Krankenhaus, Center for ALS and Other Motor Neuron Disorders, Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weyen</LastName><ForeName>Ute</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Center for ALS and Other Motor Neuron Disorders, Berufsgenossenschaftliches Universit&#xe4;tsklinikum Bergmannsheil, Bochum, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steinbach</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Hans Berger Department of Neurology, Jena University Hospital, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grosskreutz</LastName><ForeName>Julian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Precision Neurology, University of L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>R&#xf6;diger</LastName><ForeName>Annekathrin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Hans Berger Department of Neurology, Jena University Hospital, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koch</LastName><ForeName>Jan Christoph</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Universit&#xe4;tsmedizin G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lengenfeld</LastName><ForeName>Teresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Universit&#xe4;tsmedizin G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weydt</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Universit&#xe4;tsklinikum Bonn-Klinik F&#xfc;r Neurodegenerative Erkrankungen, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xfc;nther</LastName><ForeName>Ren&#xe9;</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Technische Universit&#xe4;t Dresden, Dresden, Deutschland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Site Dresden, German Centre for Neurodegenerative Diseases (DZNE), Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolf</LastName><ForeName>Joachim</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Diakonissenkrankenhaus Mannheim, Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baum</LastName><ForeName>Petra</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Universit&#xe4;tsklinikum Leipzig, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Metelmann</LastName><ForeName>Moritz</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Universit&#xe4;tsklinikum Leipzig, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dorst</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Research Site Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludolph</LastName><ForeName>Albert C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Research Site Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kettemann</LastName><ForeName>Dagmar</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Outpatient Center for ALS and Other Motor Neuron Diseases, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t Zu Berlin and Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Norden</LastName><ForeName>Jenny</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Outpatient Center for ALS and Other Motor Neuron Diseases, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t Zu Berlin and Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koc</LastName><ForeName>Ruhan Yasemin</ForeName><Initials>RY</Initials><AffiliationInfo><Affiliation>Outpatient Center for ALS and Other Motor Neuron Diseases, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t Zu Berlin and Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walter</LastName><ForeName>Bertram</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Outpatient Center for ALS and Other Motor Neuron Diseases, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t Zu Berlin and Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hildebrandt</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Ambulanzpartner Soziotechnologie APST GmbH, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;nch</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Outpatient Center for ALS and Other Motor Neuron Diseases, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t Zu Berlin and Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ambulanzpartner Soziotechnologie APST GmbH, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Meyer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Outpatient Center for ALS and Other Motor Neuron Diseases, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t Zu Berlin and Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ambulanzpartner Soziotechnologie APST GmbH, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Spittel</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Outpatient Center for ALS and Other Motor Neuron Diseases, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t Zu Berlin and Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ambulanzpartner Soziotechnologie APST GmbH, Berlin, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018908" MajorTopicYN="N">Muscle Weakness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057566" MajorTopicYN="N">Self Report</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>AM has received presentation and consulting fees from Merz Pharma GmbH &amp; Co., KGaA, and ITF Pharma GmbH. TM has received consulting fees from Cytokinetics, GSK and Desitin Arzneimittel GmbH; and has served on scientific advisory boards for Cytokinetics, GSK and TEVA. TM and CM are founders of the internet platform Ambulanzpartner and hold shares of Ambulanzpartner Soziotechnologie APST GmbH. All other authors declare that they have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>10</Day><Hour>23</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35688956</ArticleId><ArticleId IdType="pmc">PMC9187150</ArticleId><ArticleId IdType="doi">10.1038/s41598-022-13761-6</ArticleId><ArticleId IdType="pii">10.1038/s41598-022-13761-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Statland JM, Barohn RJ, McVey AL, Katz JS, Dimachkie MM. Patterns of weakness, classification of motor neuron disease, and clinical diagnosis of sporadic amyotrophic lateral sclerosis. Neurol. Clin. 2015;33(4):735&#x2013;748. doi: 10.1016/j.ncl.2015.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ncl.2015.07.006</ArticleId><ArticleId IdType="pmc">PMC4629510</ArticleId><ArticleId IdType="pubmed">26515618</ArticleId></ArticleIdList></Reference><Reference><Citation>Funke A, Spittel S, Grehl T, Grosskreutz J, Kettemann D, Petri S, et al. Provision of assistive technology devices among people with ALS in Germany: A platform-case management approach. Amyotr. Lateral Scler. Frontotemp. Degen. 2018;19(5&#x2013;6):342&#x2013;350. doi: 10.1080/21678421.2018.1431786.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1431786</ArticleId><ArticleId IdType="pubmed">29382225</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortega-Hombrados L, Molina-Torres G, Gal&#xe1;n-Mercant A, S&#xe1;nchez-Guerrero E, Gonz&#xe1;lez-S&#xe1;nchez M, Ruiz-Mu&#xf1;oz M. Systematic review of therapeutic physical exercise in patients with amyotrophic lateral sclerosis over time. Int. J. Environ. Res. Public Health. 2021;18:3. doi: 10.3390/ijerph18031074.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph18031074</ArticleId><ArticleId IdType="pmc">PMC7908444</ArticleId><ArticleId IdType="pubmed">33530383</ArticleId></ArticleIdList></Reference><Reference><Citation>Dal Bello-Haas V. Physical therapy for individuals with amyotrophic lateral sclerosis: Current insights. Degen. Neurol. Neuromuscul. Dis. 2018;8:45&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6065609</ArticleId><ArticleId IdType="pubmed">30890895</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahmati M, Malakoutinia F. Aerobic, resistance and combined exercise training for patients with amyotrophic lateral sclerosis: A systematic review and meta-analysis. Physiotherapy. 2021;113:12&#x2013;28. doi: 10.1016/j.physio.2021.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.physio.2021.04.005</ArticleId><ArticleId IdType="pubmed">34555670</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahmati M, Shamsi MM, Khoramipour K, Malakoutinia F, Woo W, Park S, et al. Baseline physical activity is associated with reduced mortality and disease outcomes in COVID-19: A systematic review and meta-analysis. Rev. Med. Virol. 2022;2:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9111124</ArticleId><ArticleId IdType="pubmed">35416354</ArticleId></ArticleIdList></Reference><Reference><Citation>Deforges S, Branchu J, Biondi O, Grondard C, Pariset C, L&#xe9;colle S, et al. Motoneuron survival is promoted by specific exercise in a mouse model of amyotrophic lateral sclerosis. J. Physiol. 2009;587(14):3561&#x2013;3572. doi: 10.1113/jphysiol.2009.169748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2009.169748</ArticleId><ArticleId IdType="pmc">PMC2742281</ArticleId><ArticleId IdType="pubmed">19491245</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalron A, Mahameed I, Weiss I, Rosengarten D, Balmor GR, Heching M, et al. Effects of a 12-week combined aerobic and strength training program in ambulatory patients with amyotrophic lateral sclerosis: A randomized controlled trial. J. Neurol. 2021;268(5):1857&#x2013;1866. doi: 10.1007/s00415-020-10354-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-10354-z</ArticleId><ArticleId IdType="pubmed">33388929</ArticleId></ArticleIdList></Reference><Reference><Citation>Barclay A, Paul L, MacFarlane N, McFadyen AK. The effect of cycling using active-passive trainers on spasticity, cardiovascular fitness, function and quality of life in people with moderate to severe Multiple Sclerosis (MS); a feasibility study. Multiple Scler. Relat. Disord. 2019;34:128&#x2013;134. doi: 10.1016/j.msard.2019.06.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2019.06.019</ArticleId><ArticleId IdType="pubmed">31260943</ArticleId></ArticleIdList></Reference><Reference><Citation>Diserens K, Perret N, Chatelain S, Bashir S, Ruegg D, Vuadens P, et al. The effect of repetitive arm cycling on post stroke spasticity and motor control. J. Neurol. Sci. 2007;253(1&#x2013;2):18&#x2013;24. doi: 10.1016/j.jns.2006.10.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2006.10.021</ArticleId><ArticleId IdType="pubmed">17241642</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridgel AL, Phillips RS, Walter BL, Discenzo FM, Loparo KA. Dynamic high-cadence cycling improves motor symptoms in Parkinson&#x2019;s disease. Front. Neurol. 2015;6:2. doi: 10.3389/fneur.2015.00194.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2015.00194</ArticleId><ArticleId IdType="pmc">PMC4557094</ArticleId><ArticleId IdType="pubmed">26388836</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardone R, Orioli A, Golaszewski S, Brigo F, Sebastianelli L, H&#xf6;ller Y, et al. Passive cycling in neurorehabilitation after spinal cord injury: A review. J. Spinal Cord Med. 2016;40(1):8&#x2013;16. doi: 10.1080/10790268.2016.1248524.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10790268.2016.1248524</ArticleId><ArticleId IdType="pmc">PMC5376131</ArticleId><ArticleId IdType="pubmed">27841091</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardone R, Langthaler PB, Bathke AC, H&#xf6;ller Y, Brigo F, Lochner P, et al. Effects of passive pedaling exercise on the intracortical inhibition in subjects with spinal cord injury. Brain Res. Bull. 2016;124:144&#x2013;149. doi: 10.1016/j.brainresbull.2016.04.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2016.04.012</ArticleId><ArticleId IdType="pubmed">27108543</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph, A. et al. Motoneuronerkrankungen, S1-Leitlinie. Leitlinien f&#xfc;r Diagnostik und Therapie in der Neurologie: Deutsche Gesellschaft f&#xfc;r Neurologie; https://dgn.org/wp-content/uploads/2021/11/030001_LL_Motoneuronerkrankungen_2021.pdf 2021.</Citation></Reference><Reference><Citation>Vandenbroucke JP, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): Explanation and elaboration. PLoS Med. 2007;4:10. doi: 10.1371/journal.pmed.0040297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.0040297</ArticleId><ArticleId IdType="pmc">PMC2020496</ArticleId><ArticleId IdType="pubmed">17941715</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2009;1(5):293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>F&#xfc;rstenau D, Klein S, Vogel A, Auschra C. Multi-sided platform and data-driven care research. Electron. Markets. 2021;2:2.</Citation></Reference><Reference><Citation>Meyer T, Kettemann D, Maier A, Grehl T, Weyen U, Grosskreutz J, et al. Symptomatic pharmacotherapy in ALS: Data analysis from a platform-based medication management programme. J. Neurol. Neurosurg. Psychiatry. 2020;91(7):783&#x2013;785. doi: 10.1136/jnnp-2020-322938.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-322938</ArticleId><ArticleId IdType="pmc">PMC7361015</ArticleId><ArticleId IdType="pubmed">32317400</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer R, Spittel S, Steinfurth L, Funke A, Kettemann D, M&#xfc;nch C, et al. Patient-reported outcome of physical therapy in amyotrophic lateral sclerosis: Observational online study. JMIR Rehabil. Assistive Technol. 2018;5:2. doi: 10.2196/rehab.8003.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/rehab.8003</ArticleId><ArticleId IdType="pmc">PMC6256108</ArticleId><ArticleId IdType="pubmed">30425026</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier A, Holm T, Wicks P, Steinfurth L, Linke P, M&#xfc;nch C, et al. Online assessment of ALS functional rating scale compares well to in-clinic evaluation: A prospective trial. Amyotroph. Lateral Scler. 2012;13(2):210&#x2013;216. doi: 10.3109/17482968.2011.633268.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2011.633268</ArticleId><ArticleId IdType="pmc">PMC3310482</ArticleId><ArticleId IdType="pubmed">22292842</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura F, Fujimura C, Ishida S, Nakajima H, Furutama D, Uehara H, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66(2):265&#x2013;267. doi: 10.1212/01.wnl.0000194316.91908.8a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000194316.91908.8a</ArticleId><ArticleId IdType="pubmed">16434671</ArticleId></ArticleIdList></Reference><Reference><Citation>Krol MW, de Boer D, Delnoij DM, Rademakers JJDJM. The Net promoter score&#x2014;an asset to patient experience surveys? Health Expect. 2015;18(6):3099&#x2013;3109. doi: 10.1111/hex.12297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hex.12297</ArticleId><ArticleId IdType="pmc">PMC5810704</ArticleId><ArticleId IdType="pubmed">25345554</ArticleId></ArticleIdList></Reference><Reference><Citation>Reichheld F. The Ultimate Question 2.0 (Revised and Expanded Edition): How Net Promoter Companies Thrive in a Customer-Driven World. Harvard Business Review Press; 2011.</Citation></Reference><Reference><Citation>Stein N, Brooks K. A fully automated conversational artificial intelligence for weight loss: Longitudinal observational study among overweight and obese adults. JMIR Diabet. 2017;2:2. doi: 10.2196/diabetes.8590.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/diabetes.8590</ArticleId><ArticleId IdType="pmc">PMC6238835</ArticleId><ArticleId IdType="pubmed">30291087</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer T, Maier A, Uzelac Z, Hagenacker T, G&#xfc;nther R, Schreiber-Katz O, et al. Treatment expectations and perception of therapy in adult patients with spinal muscular atrophy receiving nusinersen. Eur. J. Neurol. 2021;2:2.</Citation><ArticleIdList><ArticleId IdType="pubmed">33960080</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilberforce M, Poll S, Langham H, Worden A, Challis D. Measuring the patient experience in community mental health services for older people: A study of the net promoter score using the friends and family test in England. Int. J. Geriatr. Psychiatry. 2018;34(1):31&#x2013;37. doi: 10.1002/gps.4978.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gps.4978</ArticleId><ArticleId IdType="pubmed">30247775</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbohm A, Liu M, Nagel G, Peter RS, Cui B, Li X, et al. Phenotypic differences of amyotrophic lateral sclerosis (ALS) in China and Germany. J. Neurol. 2018;265(4):774&#x2013;782. doi: 10.1007/s00415-018-8735-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-018-8735-9</ArticleId><ArticleId IdType="pubmed">29392461</ArticleId></ArticleIdList></Reference><Reference><Citation>Spittel S, Maier A, Kettemann D, Walter B, Koch B, Krause K, et al. Non-invasive and tracheostomy invasive ventilation in amyotrophic lateral sclerosis: Utilization and survival rates in a cohort study over 12 years in Germany. Eur. J. Neurol. 2020;28(4):1160&#x2013;1171. doi: 10.1111/ene.14647.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14647</ArticleId><ArticleId IdType="pubmed">33210770</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbott, E.O., Malek, A.M., Lacomis, D. The epidemiology of amyotrophic lateral sclerosis. Neuroepidemiology. Handbook of Clinical Neurology2016. p. 225&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">27637961</ArticleId></ArticleIdList></Reference><Reference><Citation>Bond V, Jr, Retta T, Kumar K, Dorsey J, Gorantla VR, Millis RM. Mood responses to passive and active motion leg cycling exercise in healthy sedentary young adults. Adv. Prev. Med. 2020;2020:1&#x2013;7. doi: 10.1155/2020/7282013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/7282013</ArticleId><ArticleId IdType="pmc">PMC7066409</ArticleId><ArticleId IdType="pubmed">32181019</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>